Nucleophosmin: from structure and function to disease development by Box, Joseph et al.
Box et al. BMC Molecular Biol  (2016) 17:19 
DOI 10.1186/s12867-016-0073-9
REVIEW
Nucleophosmin: from structure 
and function to disease development
Joseph K. Box, Nicolas Paquet*, Mark N. Adams, Didier Boucher, Emma Bolderson, Kenneth J. O’Byrne 
and Derek J. Richard* 
Abstract 
Nucleophosmin (NPM1) is a critical cellular protein that has been implicated in a number of pathways including 
mRNA transport, chromatin remodeling, apoptosis and genome stability. NPM1 function is a critical requirement for 
normal cellular biology as is underlined in cancer where NPM1 is commonly overexpressed, mutated, rearranged and 
sporadically deleted. Consistent with a multifunctional role within the cell, NPM1 can function not only as a proto-
oncogene but also as a tumor suppressor. The aim of this review is to look at the less well-described role of NPM1 in 
the DNA repair pathways as well as the role of NPM1 in the regulation of apoptosis and its mutation in cancers.
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Background
Nucleophosmin (NPM1), also known as B23, No38 or 
Numatrin, is an abundant nucleolar protein found in the 
nuclei of proliferating cells. NPM1 has been documented 
as participating in ribosome biogenesis, mRNA process-
ing, chromatin remodeling, and embryogenesis (Fig.  1). 
While much is known about the function of NPM1 in 
metabolic pathways, it is becoming clear that NPM1 also 
has a critical function in maintaining genomic stability by 
functioning in various DNA repair pathways and regulat-
ing apoptosis. In this review, we shall present an updated 
overview of these roles, in particular the emerging data 
supporting a role for NPM1 in DNA repair. Lastly, we 
shall look at how NPM1 dysfunction contributes to can-
cer pathologies.
Gene organization and evolutionary history
Human NPM1 is located on chromosome 5q35 and is 
composed of 12 exons, encoding for at least two isoforms 
(Fig.  2a) [1]. NPM1.1 (or B23.1), corresponding to the 
full-length transcript, results in a 294 amino acids protein 
(35–40 kDa) abundantly expressed in all tissues. Alterna-
tively, NPM1.3 (also known as B23.2) results from the use 
of a distinct 3′ exon, and encodes for a protein expressed 
at low levels in cells, lacking the last 35 amino acids of 
the NPM1 C-terminus [2]. A third isoform NPM1.2 has 
been suggested, but so far, no biological data support this 
finding [3].
NPM1 belongs to a histone chaperones family, the 
Nucleophosmin/nucleoplasmin (NPM) family, a group 
that comprises multiple major functional members 
(NPM1, NPM2, NPM3 and the invertebrate NPM-like), 
and can be found amongst all Metazoan [4]. While this 
family is well characterized functionally, little is known 
about the evolution of these genes and proteins. At a 
glance, all members of the NPM family exhibit con-
served structural motifs; a N-terminal core domain, an 
acidic domain and a nuclear localization signal, associ-
ated with a less conserved, disorganized C-terminus 
region (Fig. 2b) [5]. Subsequently, crystallographic stud-
ies revealed a similar tertiary organization for NPM1 and 
NPM2 with monomers organized into pentameric donut-
shaped complexes [6, 7].
As simplified in Fig. 2c, phylogenetic analysis revealed 
the late emergence of the NPM1 monophyletic clade 
while, in contrast, NPM2 and NPM3 lineages appear of 
polyphyletic origin, with mammalians and amphibians 
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sequences clearly differentiated [4]. Consistent with their 
shared expression profile, localization and direct physi-
cal interaction, NPM1 and NPM3 are the most closely 
related members of the family, suggesting functional 
constraints between the two proteins [4]. Huang et al. [8] 
further suggest that NPM3 may have evolved following 
the loss of a nucleic acid binding domain of NPM1, and 
functions as an element regulating NPM1 RNA binding.
Interestingly, codon usage within the NPM gene fam-
ily indicates a strong purifying selection, materialized 
by a high rate of silent mutations which significantly 
deviates from neutrality. The highly conserved organi-
zation of NPM proteins as pentamers further supports 
the hypothesis of a strong negative selection operating 
at the structural level. Interestingly, potential sites of 
post-translational modifications are also selectively con-
strained, being conserved not only at the protein level 
but also showing a preferred codon usage [4]. Remark-
ably, these characteristics are shared with evolutionary 
features observed in histones, suggesting intertwined 
evolutionary history between the two families [9].
Despite being the most recent divergent NPM lineage, 
the functions of NPM1 are diverse and include roles in 
ribosome biogenesis [10, 11], mRNA processing [12], 
chromatin remodeling [13], embryogenesis [14], regula-
tion of apoptosis and maintenance of genome stability.
Characteristic structural features of nucleophosmin
NPM1 structural architecture is well characterized by 
three distinct regions, onto which nucleolar and nuclear 
localization motifs, nucleic acids binding domains, oli-
gomerization domains, histones binding regions, as well 
as a putative metal binding domain, have been mapped 
and described in detail [15–17] (Fig. 2a, b).
The N-terminal region is highly conserved in all mem-
bers of the Nucleoplasmin/Nucleophosmin family and 
constitutes the core domain, which mediates NPM1 
oligomerization and interactions with other proteins. 
Fig. 1 Overview of NPM1 functions within cells. NPM1 participate to many biological processes such as DNA repair, embryogenesis, likely by 
interacting with the chromatin, by binding to histones and other chromatin remodeling proteins. Importantly, NPM1 also promotes ribosome 
biogenesis
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The three dimensional structure of the human NPM1-
core has been determined by X-ray crystallography and 
showed an organization into eight β-barrels forming a 
jelly roll barrel. Further, NPM1 monomers associate as 
donut-shaped homo-pentamers (Fig.  3a, b). The distri-
bution of charges in this region is extremely asymmet-
ric with negatively charged residues clustered on one 
side of the oligomer. Two pentamers of NPM1 interact 
in a head-to-head manner to form a decamer, and are 
arranged so that a monomer of the pentameric ring 
only contacts a single monomer of the other pentamer, 
allowing structural plasticity at the pentamer–pentamer 
interface [18]. This multimeric state is modulated by 
numerous post-translational modifications, especially 
phosphorylation events that regulate the monomer-
pentamer equilibrium by promoting the disassembly of 
Fig. 2 a Superposition of NPM1 genomic structure and protein features. NPM1.1 and NPM1.3 are two splices variants resulting from the use of 
alternative codons. The two isoforms have different expression levels and localization. Ac Acidic domain, NES nuclear export signal, MB putative 
metal binding domain, NLS nucleus localization signal, NoLS Nucleolar localization signal. b Schematic structure of NPM proteins from human (not 
to scale). All proteins share a core, hydrophobic domain (blue) responsible for oligomerization and chaperone activity, followed by an acidic domain 
required for ribonuclease activity. A basic domain implicated in nucleic acid binding is common to NPM1 and NPM2, but absent in NPM3. Finally, 
only NPM1 exhibits a C-terminal aromatic stretch require for its nucleolar localization. In addition, NPM members harbor nuclear-localization signals 
(NLS), nucleolar-localization signal (NoLS), nuclear export signal (NES) and acidic clusters (a). c Simplified representation of the phylogenetic rela-
tionship within the NPM family. Inferred from [4]. The dendrogram reveals a clustering of sequences by type, rather than by species, and identifies 
NPM2 and NPM3 as polyphyletic groups
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the pentamer into unstable, unfolded monomers. This 
structural polymorphism participates in the regulation 
of NPM1 localization and function [6]. As such, oli-
gomerization of NPM1 has been linked to its nucleolar 
localization and role in cellular proliferation, while the 
monomeric form of NPM1 is associated with its role in 
the DNA damage response and induction of apoptosis 
[19].
The NPM1 central region appears unstructured and 
is marked by the presence of highly acidic regions 
composed of strings of aspartic and glutamic acids 
(A1, A2 and A3). They provide long tracks of negatively 
charged residues, known to be involved in the binding to 
Histones H1, H3, H4, H2A and H2B, potentially by mim-
icking the charges of DNA and RNA [20, 21]. It also con-
tains a nuclear localization signal.
The C-terminus of NPM1 is characterized by the pres-
ence of a basic, positively charged cluster of amino acids, 
immediately followed by a stretch of aromatic residues, 
providing an adequate platform allowing the binding 
Fig. 3 a The crystal structure of the N-terminal oligomerization domain of NPM1 organized in a decamer, with two NPM1 pentameric rings stacked 
in a head-to-head fashion. Each NPM1 monomer is depicted in a different color. Structure derived from PDB data (PDB ID: 2P1B; [18]) visualized using 
Swiss PDB viewer. b Top view of a pentameric structure shown in a, showing the organization of monomers into a donut shaped ring. c Electrostatic 
potential map of a and b, showing an asymmetric distribution of charges, with negative charges (red) on the top surface of the pentamer and 
neutral (white) to slightly positive (blue) charges
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to nucleic acids and ATP [16, 22]. These aromatic resi-
dues constitute an atypical nucleolar localization sig-
nal (NoLS), and their mutation are responsible for the 
unfolding and the aberrant NPM1 localization typical in 
acute myeloid leukemia (AML) cases.
Function of NPM1 in apoptosis
Although the best described function of NPM1 is in ribo-
some biogenesis, NPM1 also displays a critical role in 
regulating apoptosis. NPM1 expression levels have been 
implicated in controlling the cellular apoptotic response. 
In a variety of cell based models, several studies have 
demonstrated that down-regulation of NPM1 sensitizes 
cells to apoptosis, while increased levels of the protein 
protects against apoptosis [23–25]. In a disease setting, 
the balance between NPM1 expression and cell fate is 
demonstrated in hypoxia-driven cancers. For example, 
suppression of hypoxia-induced NPM1 expression pro-
motes apoptosis whereas overexpression protects from 
hypoxia-mediated cell death [26]. From a cancer perspec-
tive, elevated levels of NPM1 might promote malignant 
transformation by enabling cell survival.
Several proteins have been identified that impact 
cell survival by interacting with and regulating NPM1 
protein levels. In the nucleolus, the tumor suppressor 
p14ARF interacts with NPM1 to promote degradation of 
the protein and induce cell death (Fig. 4) [27]. However, 
the interplay between NPM1 and p14ARF is more com-
plex, with NPM1 also acting as major cellular reservoir 
of p14ARF (Fig.  4). After various stimuli NPM1 releases 
p14ARF allowing binding to MDM2 and preventing the 
proteasomal degradation of p53 (Fig.  4) [28]. Consist-
ently, depletion of NPM1 with siRNA results in increased 
apoptosis due to a greater amount of free p14ARF [28]. On 
the contrary, up-regulation of NPM1 appears to antago-
nize p14ARF and increases its nucleolar retention [29]. 
These observations provide evidence that NPM1 regu-
lates cell fate in a p53-dependent manner by directing 
p14ARF to nucleoli and preventing inhibition of MDM2 
(Fig. 4) [27, 30, 31]. Other studies have also linked NPM1 
with the tumor suppressor activity of p53. For example, 
NPM1 is also able to interact directly with MDM2, inde-
pendently of p14ARF, and act as a p53:MDM2 inhibitor to 
protect p53 from degradation (Fig.  4) [32, 33]. Interest-
ingly, NPM1 is also reported to directly associate with 
p53 [34]. However, this interaction remains contentious 
as an inability for NPM1 to interact with p53 has also 
been reported [27]. It may be that an interaction between 
NPM1 and p53 might only occur in certain cellular con-
texts. Nonetheless, this observation requires clarification.
Fig. 4 Regulation of apoptosis by NPM1. In unstressed cells, p14ARF and NPM1 form a dimer in the nucleoli, allowing MDM2 to target p53 for 
proteasomal degradation. Following a stress, such as DNA damages, p14ARF and NPM1 dissociate and relocate to the nucleus were they sequester 
MDM2, leading to the stabilization and activation of p53. p53 then induces the transcription of various genes involved in cell-cycle arrest, DNA 
repair and apoptosis
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In addition to p14ARF, MDM2 and possibly p53, NPM1 
has been reported to bind PKB/Akt in order to modulate 
cell survival. In the nucleus, Akt binds NPM1 in response 
to growth factor stimulation to protect NPM1 against 
caspase-3-mediated proteolytic degradation and promote 
cell survival [35]. Similarly, NPM1 stability is enhanced 
by interacting with erythroid differentiation-associated 
gene (EDAG), promoting acute myeloid leukemia (AML) 
cell survival [36]. In another instance, the interaction of 
GAGE with NPM1 also enables NPM1 stability to pro-
mote resistance to interferon-γ-induced apoptosis [37].
NPM1 has also been portrayed as regulating cell fate 
by modulating both the intrinsic and extrinsic apoptosis 
pathways. During the intrinsic apoptotic response, p53 
is required in the mitochondrial to enable cytochrome C 
release. Overexpression of NPM1 prevents the transloca-
tion of p53 from the nucleus to the mitochondria [38], 
suggesting that NPM1 may protect cells from apopto-
sis by reducing the mitochondrial level of p53. In acute 
promyelocytic leukemia cells expressing the NPM1-
retinoic acid receptor α (NPM1-RAR) fusion protein, 
NPM1-RAR blocked TNF-induced extrinsic apoptosis 
by inhibiting signaling to activate caspase-3 and -8 [39]. 
Similarly, mutant forms of NPM1 are indicated to impede 
apoptosis by directly inhibiting the proteolytic function 
of caspase-6 and -8 in the cytoplasm [40]. Interestingly, 
in anaplastic large-cell lymphoma cells, the cytoplas-
mic fraction of the NPM1-ALK fusion protein is solely 
responsible for inducing apoptosis by engaging the DNA-
damage response [41]. These studies suggest, at least for 
the mutant or NPM1 fusion proteins, that the cytoplas-
mic fraction of NPM1 may be required to regulate the 
apoptotic pathways.
Role of NPM1 in the DNA repair response
Loss of NPM1 function has been shown to be associated 
with increased genome instability [42]. Several studies 
have demonstrated the critical role of NPM1 in the main-
tenance of genome stability through its interaction with 
unduplicated centrosomes [42]. The phosphorylation of 
NPM1 by CDK2/Cyclin E promotes the release of NPM1 
from the centrosome during duplication; this represents 
an essential step for duplication to occur. However, dur-
ing mitosis NPM1 re-associates with the centrosomes at 
the spindle bodies and appears to be controlling centro-
some duplication [43]. Indeed, depletion of NPM1 has 
been shown to promote genome instability (unaligned 
chromosomes, micronuclei) [44, 45]. In mice, the chro-
mosomal instability associated with NPM1 depletion 
partially explains the embryonic lethality [14].
However, it has only recently become clear that NPM1 
is likely to have a direct role in the repair of DNA lesions. 
Multiple DNA repair pathways promote the repair of 
different DNA lesions and NPM1 has been implicated in 
several of these repair pathways (Fig. 5).
DNA double-strand breaks (DSB) are the most destruc-
tive and genotoxic lesions encountered by cells and as 
such complex cascades have evolved to sense, signal and 
repair these breaks. DNA DSBs can then be repaired by 
two pathways, homologous recombination (HR) and 
non-homologous end-joining (NHEJ) (reviewed in [46]). 
HR utilizes a sister chromatid as a template for repair and 
therefore can only be performed in the late S-phase and 
G2 phases of the cell cycle. In contrast, NHEJ can occur 
in any phase of the cell cycle and involves a less complex 
method of ligating the two DNA ends together. As over-
hanging DNA may be resected during this method, NHEJ 
is generally known as the more error-prone mechanism 
of DNA DSB repair. In the HR process, DSBs are detected 
and signaling pathways are initiated by the ATM/ATR 
kinases, promoting the recruitment of repair proteins, 
including nucleases that resect DNA with a 5′–3′ polar-
ity. This resection generates stretches of single stranded 
DNA, which invade into a sister chromatid, allowing it to 
act as a template for polymerase-mediated extension of 
the invading strand. Following this extension and re-liga-
tion of DNA strands this reaction then yields two intact 
and identical DNA molecules [47].
Thus far, NPM1 has only been implicated in homolo-
gous recombination (HR). Following DNA double-strand 
break induction, NPM1 is recruited from the nucleo-
lus into the nucleoplasm and binds to the chromatin 
[48]. NPM1 is phosphorylated at Threonine 199 by the 
cyclin-dependent kinases CDK1 and CDK2 during the 
cell cycle [49]. A subsequent study showed that follow-
ing induction of DNA double-strand breaks by ionizing 
irradiation, NPM1 phosphorylated on threonine 199 
localizes to sites of DNA double-strand breaks, colocal-
izing with other DNA repair proteins such as γH2AX 
and BRCA1 [50]. Phosphorylated NPM1 is recruited to 
sites of DNA marked by K63-linked ubiquitin conjugates 
in a process dependent upon the ubiquitin ligases RNF8 
and RNF168. Depletion of NPM1 or expression of non-
phosphorylatable NPM1 (T199A) leads to persistence 
of Rad51 foci suggesting that repair of DNA DSBs is not 
completed. This is further supported by the detection of 
increased DNA lesions in cells expressing NPM1 T199A. 
In contrast, cellular survival following ionizing radiation 
was not significantly affected [19]. Another study also 
analyzed γH2AX and Rad51 foci kinetics and showed 
that DNA damage also persisted in NPM1-null mouse 
embryonic fibroblast (MEF) cells [51]. Like the studies in 
human cells, NPM1-null MEFs also exhibited increased 
DNA lesions and a modest decrease in cellular sur-
vival following ionizing radiation. An anti-cancer agent, 
YTR107, was also shown to act by binding to NPM1 and 
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altering its function. YTR107 inhibits DNA repair and 
radiosensitizes cells in an NPM1-dependent process [51]. 
In light of the above it is clear that NPM1 has a role in 
DNA DSB repair, however much is still to be elucidated 
about the exact mechanism of its function in these path-
ways (Fig. 5).
Following exposure of cells to agents such as UV, DNA 
lesions may cause replication forks to stall as the repli-
cative polymerases are unable to bypass the UV-induced 
bulky lesions. In order for these stalled replication forks 
to be restarted, they can be repaired by a form of HR or 
be bypassed in a mechanism known as translesion syn-
thesis (TLS, reviewed in [52], Fig. 5). A recent study iden-
tified NPM1 as a key player of the TLS pathway [53]. This 
process enables switching of the DNA polymerase to a 
low fidelity DNA polymerase that can replicate the DNA 
across the lesion. NPM1 regulates TLS by binding to 
and protecting DNA Polymerase Eta (POLH, polη) from 
proteosomal degradation promoting its role in TLS. The 
mutated NPM1 (NPM1c+, found in 30 % of AML cases) 
was found to result in increased degradation of polη, per-
haps explaining the improved prognosis in AML patients 
with NPM1 mutations [53].
In addition to its role in DNA double-strand break 
repair and translesion synthesis, NPM1 has also been 
shown to respond to DNA lesions induced by UV light. 
The alterations to nucleotides caused by UV irradiation 
are repaired by the nucleotide excision repair pathway, a 
process that is dependent upon the PCNA homo-trimer 
(reviewed in [54]). The levels of NPM1 protein were 
shown to increase following cellular exposure to UV 
[55]. Exogenous overexpression of NPM1 was also found 
to increase cellular survival and DNA repair capacity 
following UV irradiation. Supporting a role for NPM1 in 
nucleotide excision repair (NER), it was found to tran-
scriptionally regulate the crucial NER protein PCNA 
[55]. Following UV irradiation, dephosphorylation of 
NPM1 on Threonine 199, 234 and 237 residues occurs 
in a PP1β-dependent manner. Dephosphorylation of 
these sites on NPM1 enhances the interaction between 
NPM1 and the retinoblastoma tumor suppressor protein 
(pRB), which then allows the release of E2F1 from pRB. 
E2F1 subsequently functions to transcriptionally activate 
several downstream DNA repair genes, including XPC, 
DDB2 and RPA14, facilitating DNA repair [56].
Oxidative damage to DNA is caused predominantly by 
normal cellular metabolism and is repaired by the base 
excision repair pathway (BER reviewed in [57]). NPM1 
has been shown to modulate the BER pathway through 
control of the apurinic/apyrimidinic endonuclease 1 
(APE1) protein levels and modulation of the AP-site inci-
sion activity of APE1, which is required for base exci-
sion repair (Fig.  5) [58–60]. Several nucleolar proteins 
involved in BER were also mislocalised in NPM1-defi-
cient cells, including APE1, Fen1 and LigI [61]. NPM1 
was also found to belong to a complex containing several 
BER proteins, including APE1, Fen1, Polβ and LigI [62, 
63].
NPM1 and cancer
As discussed above, NPM1 is involved in maintain-
ing genome stability and regulating apoptosis, and, as 
such, has been described as having both oncogenic and 
tumor suppressive functions. NPM1 was first associated 
with cancer where approximately one-third of anaplas-
tic large-cell non-Hodgkin’s lymphomas were found to 
Fig. 5 Overview of NPM1 functions in various DNA damage response pathways. NPM1 has been shown to modulate the BER pathway as well as 
the translesion synthesis by modulating the levels of apurinic/apyrimidinic endonuclease 1 (APE1) and polymerase eta. In the absence of NPM1 or 
with the expression of non-phosphorylatable NPM1, double-strand break repair by homologous recombination fails to be completed, however the 
exact mechanism of NPM1 function in these pathway remain to be fully elucidated
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express a fusion between NPM1 and the catalytic domain 
of anaplastic lymphoma receptor tyrosine kinase (ALK) 
[64]. In addition, 35 % of all AML patients (50–60 % in 
adults with normal karyotype) show NPM1 rearrange-
ments or mutations [65], leading the World Health 
Organization to introduce mutated NPM1 as an AML 
entity [66]. All NPM1 mutations reported occur with 
the C-terminus of the protein altering either the fold-
ing of this region or the Nucleolar localization signal 
itself. Named NPM1 Cytoplasm positive or NPM1c+, 
these mutations result in cytoplasmic localization of the 
protein, and act as dominant negative by retaining WT 
NPM1 in the cytoplasm (Fig. 6b) [67].
Patients with NPM1 mutations proved to have a bet-
ter outcome with increased complete remission and 
improved overall survival [68]. However, within this group 
of patients, the antigen expression pattern of HLADR(+) 
CD34(+) CD7(+) is associated with poor prognosis [69]. 
NPM1c+ has been shown to result in microRNAs dereg-
ulation [70], and a recent in  vitro study established that 
NPM1c+ could enhance leukemia cells adhesion, migra-
tory and invasive potential through MEK/ERK activation 
Fig. 6 a Schematic structure of NPM1 chimeric proteins found in cancers. NPM1 is represented as in Fig. 2b. b Representation of the localization 
of wild-type NPM1, NPM1c+ and NPM1-ALK fusion protein in cancer. NPM1c+ (indicated by an asterisk) is cytoplasmic and can form dimers with 
NPM1 WT, retaining it in the cytoplasm. NPM1-ALK can dimerize and localize to the cytoplasm. Inversely, NPM1-ALK can form heterodimers with 
NPM1 WT, causing ALK dislocation into the nucleus (arrow). These cells shown both aberrant localization of ALK in the nucleus, and NPM1 in the 
cytoplasm
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[71]. Notably, NPM1 mutation in a knock-in mouse 
model resulted in AML initiation [72, 73], and studies on 
MEFs have shown that NPM1 mutation results in p14ARF 
destabilization [74] and c-Myc stabilization [75].
In anaplastic large-cell lymphoma (ALCL), NPM1 
fusion with anaplastic lymphoma receptor tyrosine 
kinase (ALK) can be found in 85 % of the ALK+ ALCL, 
this results in the expression of a chimeric oncogenic 
protein formed by the C-terminus of NPM1 and the 
kinase domain of ALK (Fig.  6a) [64, 76]. In these cells 
both NPM1 and ALK exhibits aberrant localization. Fur-
ther, dimerization of NPM1-ALK leads to a constitutive 
activation of the ALK kinase (Fig. 6b) [76].
Chimeric proteins between NPM1 and the retinoic acid 
receptor-α gene (RARα) or between NPM1 and the mye-
lodysplasia/myeloid leukemia factor 1 (MLF1) have also 
been reported in rare cases of leukemia (Fig. 6a) [77, 78].
Besides leukemia, involvement of NPM1 has also been 
reported in several solid cancers. Overall, NPM1 overex-
pression is linked to high grade tumors and poor progno-
sis, as observed in brain glioblastoma [79], oral squamous 
cell carcinoma [80], non-small cells lung cancer (NSCLC) 
[51], hepatocellular carcinomas (HCC) [81], colon can-
cer [82–84], ovarian cancer [62, 85], and endometrial 
carcinoma [86]. A higher level of NPM1 has also been 
observed in prostate cancer, when compared to normal 
tissue [87, 88], promoting cells growth and invasiveness 
[89]. In bladder cancer, high levels of NPM1are not asso-
ciated with tumor grade, but with cancer progression, 
recurrence, and poor prognosis [90]. NPM1 overexpres-
sion has also been reported in thyroid cancer [91], with 
thyroid cancer cell lines showing NPM1 mislocaliza-
tion in the absence of the mutations observed in AML 
patients [92].
However, low levels of NPM1 have also been observed 
in some cancers, such as gastric cancers (mRNA and 
protein) compared to normal tissue [93]. In breast can-
cer, low NPM1 levels are also associated with poor out-
come, independently of the molecular subtype, with 
granular staining of NPM1 correlating with poor prog-
nosis [94].
Since NPM1 is overexpressed in many types of cancer 
and because of its role in genome stability, it could be a 
potential target for new cancer therapy strategies. Differ-
ent molecules have been trialed to induce cell death by 
destabilizing NPM1 [95–98] or inhibiting its interaction 
with other DNA repair proteins [99]. Recent studies have 
focused on combining NPM1 inhibition with a DNA 
damaging agent, for instance ionizing radiation [51, 100], 
or a cytotoxic drug [101]. Other strategies are aiming 
specifically at NPM1c+ itself [102], or in combination 
with damage induction by increasing oxidative stress in 
cells [103–106].
Frontiers
As summarized here, NPM1 plays multiple roles within 
human cells while the best documented is in RNA trans-
port and ribosome biogenesis, it is clear that NPM1 also 
plays a critical role in the regulation of apoptosis and in 
the maintenance of genomic homeostasis.
Genome instability is one of the underlying causes of 
cellular transformation and cancer development. Once a 
cancer does form, genome instability becomes a common 
feature seen as a universal hallmark of all cancers [107]. 
This instability provides the cancer the ability to evolve 
and adapt to the environment in which it is located; fur-
ther, defects in the apoptosis pathways allow the cancer 
cell to cope and survive with levels of genetic instability 
that would normally induce cell death.
Given the critical role NPM1 plays in genome stability 
and apoptosis it is hardly surprising that NPM1 dysfunc-
tion is a frequent feature in cancers. Indeed, as evidence 
of NPM1 function in DNA repair pathways increases, it 
explains at least in part the genetic instability associated 
with cancers such as AML. Further, NPM1 deregula-
tion or mutation will suppress the ability of that cell to 
respond to apoptotic stimuli, allowing for the tolerance 
of the genetic instability. Consistent with a role in genetic 
instability and specifically the repair of double-strand 
DNA breaks we see that AML patients with a mutated 
NPM1 have a >2 fold higher odds of achieving com-
plete remission as compared to patients with a wild type 
NPM1 [108]. NPM1 in cancer is most strikingly high-
lighted in acute myeloid leukemia where approximately 
30  % of patients will have a mutation or fusion event 
implicating NPM1.
Despite the importance of NPM1 in genome stability it 
is clear that we do not fully understand how NPM1 func-
tions in the repair of DNA damage. We know that NPM1 
moves to sites of double-strand DNA breaks within the 
genome, but we do not yet understand how NPM1 func-
tions at those break sites. We do not know if NPM1 binds 
to nucleic acids at those sites or if it is involved in remod-
eling chromatin. It is clear, however, that understand-
ing how NPM1 participates in DNA repair and genome 
stability will help to delineate the role of NPM1 in both 
normal and cancerous cells. This will perhaps provide 
insights into why NPM1 dysfunction is a marker of drug 
and radiation sensitivities.
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